XNCR
Xencor, Inc.
Biotechnology · Healthcare · United States
29.82
close · 2026-10-30
value
69
cheaper than peers69
quality
54
stronger fundamentals54
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | -0.9% | 82 |
| earnings yield, 3 years ago | -3.1% | 78 |
| earnings yield, 2 years ago | -7.0% | 69 |
| cash flow yield, 2 years ago | -4.5% | 67 |
| earnings yield, latest year | -4.2% | 65 |
| cash flow yield, latest year | -6.2% | 59 |
| earnings yield, 1 year ago | -12.0% | 55 |
| cash flow yield, 1 year ago | -9.5% | 50 |
| price to book | 4.40× | 39 |
| price to sales | 21.12× | 35 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -29.1% | 66 |
| operating margin | -72.4% | 58 |
| revenue growth | 17.5% | 51 |
| debt to equity | 33.8% | 36 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$94.5M |
| employees | 260 |
| first trade | 2013-12-03 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.24 | -3.58 | -2.08 | -0.93 |
| free cash flow | -$138.3M | -$211.7M | -$99.2M | -$18.9M |
| net income | -$91.9M | -$232.6M | -$133.1M | -$55.2M |
| revenue | $125.6M | $110.5M | $174.6M | $164.6M |
| unusual items | $92.3M | -$51.9M | -$395,000 | $23.3M |